Amgen Inc
AMGN Real Time Price USD$AMGN stock is featured in our Dan Meuser, Sheldon Whitehouse, and Shelley Moore Capito strategies.
See All StrategiesRecent trades of AMGN by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by AMGN's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$7,500 Jul 14, 2025 Issue: Health Issues
-
$60,000 Apr 21, 2025 Issue: Health Issues Medicare/Medicaid Immigration
-
$3,610,000 Apr 21, 2025 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Copyright/Patent/Trademark Tariff (miscellaneous tariff bills)
-
$60,000 Apr 21, 2025 Issue: Health Issues Budget/Appropriations
-
$60,000 Apr 21, 2025 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Budget/Appropriations Labor Issues/Antitrust/Workplace Copyright/Patent/Trademark
-
$50,000 Apr 21, 2025 Issue: Health Issues
-
$80,000 Apr 21, 2025 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
-
$10,000 Apr 20, 2025 Issue: Health Issues
-
$60,000 Apr 18, 2025 Issue: Medicare/Medicaid
-
$50,000 Apr 18, 2025 Issue: Health Issues
-
$50,000 Apr 18, 2025 Issue: Medicare/Medicaid
-
$50,000 Apr 17, 2025 Issue: Medicare/Medicaid
-
$7,500 Apr 15, 2025 Issue: Health Issues
-
$60,000 Apr 15, 2025 Issue: Health Issues Medicare/Medicaid Budget/Appropriations
-
$30,000 Apr 11, 2025 Issue: Health Issues
-
$2,980,000 Feb 04, 2025 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Copyright/Patent/Trademark
-
$60,000 Jan 22, 2025 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Budget/Appropriations Labor Issues/Antitrust/Workplace Copyright/Patent/Trademark
-
$2,780,000 Jan 21, 2025 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Copyright/Patent/Trademark
-
$60,000 Jan 21, 2025 Issue: Health Issues Medicare/Medicaid Immigration
-
$60,000 Jan 21, 2025 Issue: Medicare/Medicaid Pharmacy
-
$50,000 Jan 20, 2025 Issue: Health Issues
-
$60,000 Jan 20, 2025 Issue: Health Issues
-
$20,000 Jan 20, 2025 Issue: Health Issues
-
$50,000 Jan 20, 2025 Issue: Medicare/Medicaid
-
$60,000 Jan 19, 2025 Issue: Medicare/Medicaid
-
$50,000 Jan 18, 2025 Issue: Health Issues
-
$60,000 Jan 16, 2025 Issue: Health Issues Medicare/Medicaid Budget/Appropriations
-
$7,500 Jan 16, 2025 Issue: Health Issues
-
$50,000 Jan 16, 2025 Issue: Medicare/Medicaid
-
$80,000 Jan 15, 2025 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
-
$30,000 Jan 13, 2025 Issue: Health Issues
-
$80,000 Dec 15, 2024 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
-
$15,000 Oct 21, 2024 Issue: Health Issues
-
$60,000 Oct 21, 2024 Issue: Health Issues
-
$2,770,000 Oct 21, 2024 Issue: Copyright/Patent/Trademark Taxation/Internal Revenue Code Medicare/Medicaid Health Issues
-
$60,000 Oct 21, 2024 Issue: Immigration Medicare/Medicaid Health Issues
-
$60,000 Oct 21, 2024 Issue: Pharmacy Medicare/Medicaid
-
$50,000 Oct 21, 2024 Issue: Medicare/Medicaid
-
$50,000 Oct 21, 2024 Issue: Health Issues
-
$50,000 Oct 19, 2024 Issue: Health Issues
-
$60,000 Oct 18, 2024 Issue: Budget/Appropriations Medicare/Medicaid Health Issues
-
$60,000 Oct 18, 2024 Issue: Law Enforcement/Crime/Criminal Justice Copyright/Patent/Trademark Labor Issues/Antitrust/Workplace Budget/Appropriations Taxation/Internal Revenue Code Medicare/Medicaid Health Issues
-
$7,500 Oct 17, 2024 Issue: Health Issues
-
$60,000 Oct 15, 2024 Issue: Medicare/Medicaid
-
$30,000 Oct 14, 2024 Issue: Health Issues
-
$50,000 Oct 13, 2024 Issue: Medicare/Medicaid
-
$60,000 Jul 22, 2024 Issue: Immigration Medicare/Medicaid Health Issues
-
$2,740,000 Jul 22, 2024 Issue: Copyright/Patent/Trademark Taxation/Internal Revenue Code Medicare/Medicaid Health Issues
-
$60,000 Jul 22, 2024 Issue: Pharmacy Medicare/Medicaid
-
$60,000 Jul 22, 2024 Issue: Budget/Appropriations Medicare/Medicaid Health Issues
-
$50,000 Jul 22, 2024 Issue: Health Issues
-
$50,000 Jul 20, 2024 Issue: Health Issues
-
$50,000 Jul 19, 2024 Issue: Medicare/Medicaid
-
$5,000 Jul 19, 2024 Issue: Health Issues
-
$80,000 Jul 19, 2024 Issue: Taxation/Internal Revenue Code Health Issues Medicare/Medicaid
-
$90,000 Jul 19, 2024 Issue: None
-
$7,500 Jul 15, 2024 Issue: Health Issues
-
$60,000 Jul 15, 2024 Issue: Medicare/Medicaid
-
$30,000 Jul 15, 2024 Issue: Health Issues
-
$60,000 Apr 22, 2024 Issue: Taxation/Internal Revenue Code Health Issues Medicare/Medicaid
-
$60,000 Apr 22, 2024 Issue: Immigration Medicare/Medicaid Health Issues
-
$7,500 Apr 22, 2024 Issue: Health Issues
-
$60,000 Apr 22, 2024 Issue: Budget/Appropriations Medicare/Medicaid Health Issues
-
$50,000 Apr 22, 2024 Issue: Health Issues
-
$50,000 Apr 21, 2024 Issue: Medicare/Medicaid
-
$50,000 Apr 19, 2024 Issue: Health Issues
-
$90,000 Apr 19, 2024 Issue: None
-
$3,330,000 Apr 19, 2024 Issue: Copyright/Patent/Trademark Taxation/Internal Revenue Code Medicare/Medicaid Health Issues
-
$30,000 Apr 12, 2024 Issue: Health Issues
-
$60,000 Apr 12, 2024 Issue: Medicare/Medicaid
-
$60,000 Feb 07, 2024 Issue: Budget/Appropriations Copyright/Patent/Trademark Medicare/Medicaid Health Issues
-
$60,000 Jan 22, 2024 Issue: Taxation/Internal Revenue Code Health Issues Medicare/Medicaid
-
$50,000 Jan 22, 2024 Issue: Medicare/Medicaid
-
$60,000 Jan 22, 2024 Issue: None
-
$50,000 Jan 22, 2024 Issue: Health Issues
-
$3,550,000 Jan 19, 2024 Issue: Copyright/Patent/Trademark Taxation/Internal Revenue Code Medicare/Medicaid Health Issues
-
$60,000 Oct 20, 2023 Issue: Taxation/Internal Revenue Code Health Issues Medicare/Medicaid
-
$60,000 Oct 20, 2023 Issue: Budget/Appropriations Medicare/Medicaid Health Issues
-
$50,000 Oct 20, 2023 Issue: Health Issues
-
$50,000 Oct 19, 2023 Issue: Medicare/Medicaid
-
$50,000 Oct 19, 2023 Issue: Health Issues
-
$60,000 Oct 16, 2023 Issue: Health Issues Medicare/Medicaid
-
$2,140,000 Oct 16, 2023 Issue: Copyright/Patent/Trademark Taxation/Internal Revenue Code Medicare/Medicaid Health Issues
-
$1,950,000 Jul 21, 2023 Issue: Copyright/Patent/Trademark Taxation/Internal Revenue Code Medicare/Medicaid Health Issues
-
$50,000 Jul 20, 2023 Issue: Health Issues
-
$60,000 Jul 20, 2023 Issue: Taxation/Internal Revenue Code Health Issues Medicare/Medicaid
-
$50,000 Jul 19, 2023 Issue: Taxation/Internal Revenue Code Medicare/Medicaid
-
$50,000 Jul 19, 2023 Issue: Health Issues
-
$60,000 Jul 18, 2023 Issue: Trade (domestic/foreign) Budget/Appropriations Medicare/Medicaid Health Issues
-
$60,000 Jul 14, 2023 Issue: Taxation/Internal Revenue Code Budget/Appropriations Medicare/Medicaid
-
$60,000 Jan 20, 2023 Issue: Taxation/Internal Revenue Code Medicare/Medicaid
-
$50,000 Jan 20, 2023 Issue: Health Issues
-
$80,000 Jan 20, 2023 Issue: Taxation/Internal Revenue Code Health Issues Medicare/Medicaid
-
$50,000 Jan 19, 2023 Issue: Health Issues
-
$80,000 Jan 14, 2023 Issue: Budget/Appropriations Health Issues Medicare/Medicaid
-
$80,000 Oct 20, 2022 Issue: Medicare/Medicaid
-
$60,000 Oct 20, 2022 Issue: Taxation/Internal Revenue Code Medicare/Medicaid
-
$60,000 Oct 20, 2022 Issue: Budget/Appropriations Copyright/Patent/Trademark Medicare/Medicaid Health Issues
-
$50,000 Oct 20, 2022 Issue: Health Issues
-
$50,000 Oct 19, 2022 Issue: Health Issues
Estimated quarterly lobbying spending
AMGN Revenue by Segment or Geography
New patents grants
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to AMGN
Recent picks made for AMGN stock on CNBC
ETFs with the largest estimated holdings in AMGN
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $AMGN stock a Buy, Sell, or Hold?
- What is the price target for $AMGN stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $AMGN stock?
- Who owns the most shares of $AMGN stock?
- What funds own $AMGN stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view AMGN Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.